Annovis Bio, Inc. (NYSE: ANVS) is a clinical-stage biotechnology Company that is developing a pipeline of drugs that target the treatment of Alzheimer’s and other neurodegenerative diseases through improvement of Axonal Transport. The Company is working on therapeutics for Alzheimer’s disease (AD), Parkinson’s disease (PD),...
Graybug Vision, Inc. (NASDAQ: GRAY) is a clinical-stage biopharmaceutical company that is striving to create novel treatment solutions for diseases that combat vision—threatening diseases and save sight delivering a much better quality of life for patients. The Company is developing therapies for treatment of chronic...
Enzolytics Inc. (OTCPK: ENZC) is leveraging over 40 years of drug development experience to develop proprietary antiviral peptides and monoclonal antibodies for the treatment of Infectious Diseases. The Company is using a combination of patented-HIV therapeutics and an exclusive methodology, for creating fully human IgG1...
Biogen, Inc. (NASDAQ: BIIB) ADUHELM™ (aducanumab-avwa), scored an approval from the U.S. Food and Drug Administration (FDA), to become the first drug approved after 2003 for the treatment of Alzheimer’s disease, which specifically addresses the underlying cause of the disease, by removing amyloid beta from...
Akebia Therapeutics, Inc. (NASDAQ: AKBA), a biopharmaceutical developing cutting-edge therapies for the treatment of patients with kidney diseases, announced the acceptance of the filing of its New Drug Application (NDA) for its lead product candidate, Vadadustat, a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, intended for...
Biotech Companies continue to show resurgence even in these challenging times, with more and more companies persevering with bringing their clinical candidates to fruition. While Vaccine development and therapeutics to combat the COVID-19 pandemic are at the forefront of development activities in the biotech sector,...
Scholar Rock Holding (NASDAQ: SRRK), a clinical-stage biopharmaceutical Company, announced the grant of a Fast-Track Designation for apitegromab, a selective inhibitor of myostatin activation, intended for the treatment of Spinal Muscular Atrophy (SMA) by the U.S. Food and Drug Administration (FDA). The candidate has previously...
Scopus BioPharma, Inc. (NASDAQ: SCPS), a biopharmaceutical company, announced the approval of an investigational drug application (IND) for CpG-STAT3siRNA, an immuno-oncology RNA therapy intended for the treatment of multiple cancers. CpG-STAT3siRNA, or CO-sTiRNA™, the company’s lead product candidate is a first-in-class, targeted immuno-oncology gene therapy and...
While Industries across the globe are grappling with the pandemic and its impact on their operations, Technology Industry has been focused on minimizing the impact and marching ahead with its innovations and breakthroughs, be it electric charging, semiconductor solutions or critical communication systems. We take a...
A clinical stage Immuno-oncology company, Surface Oncology, Inc. (NASDAQ: SURF) is developing a diverse pipeline of candidates that target the immune system to combat various forms of cancer. The Company’s pipeline consists of candidates in four key areas namely macrophages and natural killer cells,...
